Similar to published literature, in our study cohort with castration resistant prostate cancer patients we found an increased rate of AR mutation frequency among those who received ARTA (19%) compared to those who did not (8%) as well as co-occurrence of AR amplification together with mutation which was not seen pre-ARTA exposure. The gene discussed is AR; the disease is Familial prostate cancer.